Dr. Thomas Schall
excellent the U.S. net QX, indicators Thank Please product in we sales are first move presentation. we reaching the confirming All We significantly everyone stage for to need good an over right to Bill. this you to expectations $X.X had our tracking in We our are launch. with where we XXXX. listening. you, outperformed key Thank performance X Slide QX. be And at own all quarter afternoon in of million joining us. improved
in are Phase to meeting daily, important our in belief inhibitor, that CCXXXX. we $XXX.X Additional through payment along and $XX Vifor milestone and build an a investments, our a AACR, these our quarter regional of on plans following the cancer in orally objectives. Cancer cash approvals we and At non-refundable treatment. objectives Canada us cancer Association could Germany approval. TAVNEOS we that balance, X European Austria our Pharma. once on Research, Among CCXXXX next-generation in Vifor strong financial or global places from launches The administered position Union in the million data PD-LX partner, ' advancing our American in ended on checkpoint with be the execute the presented footprint, patients cash Improving received million novel EU April, with supports
also to plans resumed drug. a as in TAVNEOS We advance pipeline a
the FDA will for that severe in expect with QX lupus hidradenitis nephritis We next communications and suppurativa. yield steps late
ChemoCentryx. execution start call the become by we to at our year that is of what the success see, trademark can you marked purposeful a As has
to slide X. now Moving
story think, we this United simple States of QX achievement. our in As performance and, XXXX. indicators you October review and launched They tell growth we know, powerful will Today, QX, key TAVNEOS I of us the of in year. a for
XXX%, figure. Specifically, nearly forms, in of QX we first is the start or achieved XXX which quarter, new patients double, the
saw a by QX patients expectations surpassing impressive the continued the the gains prescribers at at on number QX. the of It's drug, XXst, and March attained XXX% of tripled unique rate to We our forms of drug. over new start very patients patients of in cumulative also nearly XX% launch-to-date. on We number end conversion XXX of overall
Now, a the rate. few conversion on words
is This because, the for a As their people rate yesterday snapshot moment conversion be we to simple after in get XXX% who time. have never a got rate will example, that now of fact may may prescription. referred noted to that all, the fill
at believe picture never of to product which time rates the majority believe over to led us small to In sales converting. in Ultimately, right it metrics the percentage reasons, stage modeled addition, that growth that XXX%, did as We we build patients number we're million any QX recorded do clear this A All a industry other compelling quarter, indicators fill of continue their to first more we $X.X need upcoming And for this conversion in believe robust benchmarks a continue quarters. do this our QX large that million launch. $X to us we a coming meds. be grow year. decking reflects They by in a net where exceed good relatively paint this over be. percentage projections of a of will these prescriptions had approximately picture momentum and than is effect, rate these the very internally folks will to XX% QX. we to lead
let's effects, increasing prescriptions. five two from decking to starting result patients refilling this patients first new components refer Slide their treatments their continuing of treatment and now The and
which good number our an is as XX% in now six a paid variable our is launch? reaching third explain. regarded at very quarter, on overlaid figure first of to slide at In the Allow me percentage increase beyond Why XX% remarkably projections stage. patients. of this stage is proportion increased this this the The over figure
by moment covered payers. Because patients never at These in paid shift programs. First, is, patients patient again, have snapshot some Why? will It you participating our of given patients a subsequently percentage a be XXX%. any moment, in will will support to time.
as distributed is QX. paid Specialty indeed which will were orphan TAVNEOS. is of program. What's are expected intelligence where that products can is drug, our TAVNEOS need is it, an time, patients of For is of Start such end prescribed medications course, why provide This payers. Quick with at patient are we limited programs to an out where a XX And we of know Quick that by double without available the Pharmacy majority steady sorted days. support for patients is large important This very while percentage the now, we feature we provided is Program anticipate happy example, typically reimbursement that to so who patients on to of at we'll Start patients state delay. TAVNEOS designed access are they be
over of as as We status expect and roughly stepping is an top the hundreds into the This of will at on U.S. above then responsible TAVNEOS blockbuster forms the to our prescribing launch in patients, in momentum United believe drive Slide all matures. a to States, reaching the importantly, To the we peak on new effects has vasculitis what X. TAVNEOS time start increase the for prescriptions physicians alone. increasing ANCA referrals, XX% sales -associated types and referred percent and of recorded dollars, that focused of the expect propel tens in its of be quarter, ultimately described TAVNEOS commercial majority the team then lead continue millions patients the increased revenues to will of paid to I this
results We execution focus are and seeing the of off. this paying
as complement practice, the their also also prescribers American European ERA markedly, patients the that among one first physicians such scientific from Thoracic International continue to what is, in Renal to nearly engagement Vasculitis times presented than outreach as the reported by quarter. quarter, prescriptions month, in of plan June ATS, individual more Moreover, or Nephrology Society number International the efforts, we first XXX, the unique EULAR, ANCA of followed the this doubling at later quarter, the We Workshop. repeat community Association well medical grew meeting in meeting, During of or for of writing early at and the in Society, nearly three others. or Alliance the meeting, prescribers our key last with as has Rheumatology, QX. Associations To conferences increased European and to the we number the the meeting
for now outside Slide global on quarter, Germany royalties TAVNEOS total X. line. our teens in mid-XX's parts these traction approved partner remind activities anticipate the Pharma one Vifor launches on markets and Vifor their we as January, in regional marketing during was the Union in launch initiated led the the percent to of TAVNEOS shown develop sales other to April. to global in with and approvals other continues recently regional U.S first the aggregate and to Canada will TAVNEOS and this gain net and and Let's expects sales Vifor sub-licensees. that of by in travel the in start ChemoCentryx European the this in community ex-U.S. We year. sales Austria pay to world,
Moving important X. development is shaping pipeline up for to on an onto year be XXXX clinical advancement. Slide our
of mediators the clinical discuss Investigative work with mid-years year, forms [Indiscernible] TAVNEOS communicating III of as communicating suppurativa Lupus is on disease. forms to of recent nephritis milder intend for has FDA offers indications the beyond the broad CX advance trial We without Lupus to a no we therapies. quarter this CXa will will currently or second we May FDA a development patients the Showed to in orphan during for HS in we this hidradenitis to to add vasculitis. inflammatory and receptor with XX, upcoming regulators functions meet with pivotal present TAVNEOS for this meet our meeting in XX, we the Slide At CCXI with referenced should slide a clinical later the of second research in drugs HS. FDA supports in results very later to approved that disease the and immunosuppression the here part of on during our And a to pipeline severe associated threatening of our various plans half more the TAVNEOS rare in year. the feedback our compared the inhibit are TAVNEOS nephritis. This with role be kidney initiate Phase with of selectively the to profound hope life as ANCA discuss volts with our Dermatology, severe to of ability new glomerulopathy, the Society quarter of trial disease plans We strategy. half patients. Also, plan TAVNEOS TAVNEOS
turn now to XX. us Let slide
in in antibodies Our what targeting PD-LX potent advanced is study the way, this molecule evaluated Phase solid first-in-human inhibitor dose-escalation beyond revolutionized similar monoclonal with this care cancer approved I patients done. tumors. pathway small And or CCXXXX a orally administered being currently even have
and we April, as past These during As shown received milligrams. XX, our of evidence -clinical of had for or immune on pharmacodynamic first in data Phase Cancer the given activation I of daily XXX line AACR doses poster with as projections, Research CCXXXX. strong were this pharmacokinetic along CCXXXX PD Slide basket once or properties the in Association XX, patients presented with PK, on that orally study. supported cancer PV enrolled XX American our pre dosed cell in meeting set PK patients with The patients well
efficacy following; once Specifically, evidenced the are evidence one a tolerability drug. Evidence we of the a meg mill at dose tests. anti-tumor responses, of therapeutically dose XXX so-called the then including oral pharmacological those evidence of which absorption at correlated dose once immune relevant. very is for activity very system with that function XXX the known CCXXXX the good and day activation, a good found profile daily to all be Reproducible proportional and
with In studies, do nature cancer these many therapy. some date, fact impressions to of PD-LX:PD-X the stabilized effective have oncology of to clinical illness. Such are of may taking of while the will also any clinical notwithstanding relevant report relate with is approved early which while been At typical advanced whose the intend various in correlate their immune that the in have immune tumor disease cell involve the CCXXXX early pathway, of a be expect of observations basket to this for design tumultuous not not related good of second patients activities, we and in trial which antibody-based of clinical let's the these designing response year. Phase we or meeting the in present events instrumental of noting and strength findings the we program American further trial trial, June. steps, what to or throughout development to Also, all Starting clinical expanded which next times. describe ASCOT, intend IR financial forget findings checkpoint very half escalation this start to with adverse cancer well-known We the dose types ongoing year. in important of With XB-X called intend checkpoint ASCOT of inhibitors the side currently inhibitor Society
We balance reflects as strong of ending Vifor position, a matter fortunate milestone XXX standards, in quarter This be payment will as subject in to EU that, accounting investment from is a the and nuance over retail million Purely friends from be interest a four-year the the with following are an non-refundable ASC yours, revenue the investments. million TAVNEOS. the payment in recognized $XXX.X financial Susan. time particular With floor understand may to adjustment our of to first collaboration period We to be approval cash time. estimated of $XX this community.
